344 related articles for article (PubMed ID: 35053202)
1. Site-Specific Proteasome Inhibitors.
Kisselev AF
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053202
[TBL] [Abstract][Full Text] [Related]
2. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
3. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
4. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
5. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
6. Proteasome Inhibitor Drugs.
Fricker LD
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
[TBL] [Abstract][Full Text] [Related]
7. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
8. In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted.
Porras-Yakushi TR; Reitsma JM; Sweredoski MJ; Deshaies RJ; Hess S
J Proteomics; 2021 Jun; 241():104197. PubMed ID: 33848640
[TBL] [Abstract][Full Text] [Related]
9. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
11. The immunoproteasome as a target in hematologic malignancies.
Kuhn DJ; Orlowski RZ
Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
[TBL] [Abstract][Full Text] [Related]
12. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
13. Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity of Human Organic Anion Transporter 1.
Fan Y; You G
Mol Pharmacol; 2020 Jun; 97(6):384-391. PubMed ID: 32234809
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
15. Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1.
Velez B; Razi A; Hubbard RD; Walsh R; Rawson S; Tian G; Finley D; Hanna J
Proc Natl Acad Sci U S A; 2023 Dec; 120(51):e2308417120. PubMed ID: 38091293
[TBL] [Abstract][Full Text] [Related]
16. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
18. Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism.
Wang J; Fang Y; Fan RA; Kirk CJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769030
[TBL] [Abstract][Full Text] [Related]
19. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
Kegyes D; Gulei D; Drula R; Cenariu D; Tigu B; Dima D; Tanase A; Badelita S; Buzoianu AD; Ciurea S; Ghiaur G; Terpos E; Ciechanover A; Einsele H; Tomuleasa C
Blood Rev; 2023 Sep; 61():101100. PubMed ID: 37291017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]